MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scotto, K. W.
Right arrow Articles by Johnson, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scotto, K. W.
Right arrow Articles by Johnson, R. A.
Molecular Interventions 1:117-125 (2001)
© 2001 American Society of Pharmacology and Experimental Therapeutics

Review

Transcription of MDR1

A Therapeutic Target

Kathleen W. Scotto, Ph.D. and Robert A. Johnson

Memorial Sloan-Kettering Cancer Center and, Weill Graduate School of Cornell University, 1275 York Avenue, New York, NY 10021

Correspondence: Address correspondence to KWS. E-mail k-scotto{at}mskmail.mskcc.org; fax 212-639-8972.


The sea squirt Ecteinascidia turbinata, shown above as grape-like clusters of sheathed individuals, is the source of a novel chemotherapeutic agent. The organism produces ET-743, which appears to interfere, in an exquisitely specific manner, with cellular transcription programs involved in cancer. (Image provided by PharmaMar.)

Two decades ago, the overexpression of P-glycoprotein (Pgp) was first demonstrated to mediate the energy-dependent efflux of a variety of chemotherapeutic agents from tumor cells, resulting in the development of multidrug resistance (MDR). Not surprisingly, this discovery triggered an ongoing search for agents that would inhibit Pgp function, with the hope that by doing so the MDR phenotype could be reversed. As our understanding of Pgp function and pharmacokinetics has increased, this quest has become more urgent, as well as more complex.




This article has been cited by other articles:


Home page
 The OncologistHome page
J. R. Bertino
Transfer of drug resistance genes into hematopoietic stem cells for marrow protection.
Oncologist, October 1, 2008; 13(10): 1036 - 1042.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. Manoharlal, N. A. Gaur, S. L. Panwar, J. Morschhauser, and R. Prasad
Transcriptional Activation and Increased mRNA Stability Contribute to Overexpression of CDR1 in Azole-Resistant Candida albicans
Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1481 - 1492.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
H. Shen, W. Xu, Z. Wu, H. Tang, Y. Xie, and X. Zhong
Down-regulation of WT1/+17AA gene expression using RNAi and modulating leukemia cell chemotherapy resistance
Haematologica, September 1, 2007; 92(9): 1270 - 1272.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Mahadevan and A. F. List
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
Blood, October 1, 2004; 104(7): 1940 - 1951.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Xu, D. Ye, M. Fisher, and R. L. Juliano
Selective Inhibition of P-glycoprotein Expression in Multidrug-Resistant Tumor Cells by a Designed Transcriptional Regulator
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 963 - 971.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.